1 |
Burster T, Traut R, Yermekkyzy Z, Mayer K, Westhoff MA, Bischof J, Knippschild U. Critical View of Novel Treatment Strategies for Glioblastoma: Failure and Success of Resistance Mechanisms by Glioblastoma Cells. Front Cell Dev Biol 2021;9:695325. [PMID: 34485282 DOI: 10.3389/fcell.2021.695325] [Reference Citation Analysis]
|
2 |
Xu P, Westhoff MA, Hadzalic A, Debatin KM, Winiarski L, Oleksyszyn J, Wirtz CR, Knippschild U, Burster T. Diisothiocyanate-Derived Mercapturic Acids Are a Promising Partner for Combination Therapies in Glioblastoma. ACS Omega 2022;7:5929-36. [PMID: 35224353 DOI: 10.1021/acsomega.1c06169] [Reference Citation Analysis]
|
3 |
Bausart M, Préat V, Malfanti A. Immunotherapy for glioblastoma: the promise of combination strategies. J Exp Clin Cancer Res 2022;41. [DOI: 10.1186/s13046-022-02251-2] [Reference Citation Analysis]
|
4 |
Setlai BP, Hull R, Bida M, Durandt C, Mulaudzi TV, Chatziioannou A, Dlamini Z. Immunosuppressive Signaling Pathways as Targeted Cancer Therapies. Biomedicines 2022;10:682. [DOI: 10.3390/biomedicines10030682] [Reference Citation Analysis]
|
5 |
Dapash M, Hou D, Castro B, Lee-Chang C, Lesniak MS. The Interplay between Glioblastoma and Its Microenvironment. Cells 2021;10:2257. [PMID: 34571905 DOI: 10.3390/cells10092257] [Reference Citation Analysis]
|